MedTrace Logo

A Study of NPT189 in Healthy Subjects

NCT03610035 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2019-08-15

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety and tolerability of single dose of NPT189 in healthy volunteers. The study will also evaluate the pharmacokinetic characteristics of NPT189.

Conditions

  • Amyloidosis

Interventions

DRUG

NPT189

IgG1 Fc-GAIM fusion protein, a recombinant fusion protein

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Proclara Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Proclara Biosciences · Proclara

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-24
Primary Completion
2019-02-17
Completion
2019-02-17

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03610035 on ClinicalTrials.gov